Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Diabetes Care

• Publication date

  2003-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.26.11.3194PMID 14578270
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

  2000cited by this paper
• Relation between coronary artery disease, aortic stiffness, and left ventricular structure in a population sample.

  1998cited by this paper
• THIAZOLIDINEDIONES: TOOLS FOR THE RESEARCH OF METABOLIC SYNDROME X

  1998cited by this paper
• The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.

  1995cited by this paper
• Estimation of total arterial compliance: an improved method and evaluation of current methods.

  1986cited by this paper

• Hyperinsulinemia rather than insulin resistance itself induces blood pressure elevation in high fat diet-fed rats

  2020cites this paper
• Glitazone 2006 Glitazone 2006 – ein Update

  2019cites this paper
• Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents

  2015cites this paper
• Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.

  2015cites this paper
• Rosiglitazone/Metformin

  2012cites this paper
• Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy

  2012cites this paper
• Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes

  2011cites this paper
• Effects of thiazolidinediones beyond glycaemic control.

  2009cites this paper
• Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.

  2009cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

  2008cites this paper
• Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?

  2008cites this paper
• Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update

  2008cites this paper
• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

  2008cites this paper
• Pleiotropic effects of thiazolidinediones

  2008cites this paper
• Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.

  2007cites this paper
• Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone.

  2007cites this paper
• A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.

  2007cites this paper
• The anti-atherogenic effects of thiazolidinediones.

  2007cites this paper
• Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.

  2006cites this paper
• The effects of thiazolidinediones on blood pressure levels – A systematic review

  2006cites this paper
• A Meta‐Analysis of the Effect of Thiazolidinediones on Blood Pressure

  2006cites this paper
• Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect.

  2006cites this paper
• Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study*

  2006cites this paper
• Glitazone 2006 - ein Update

  2006cites this paper
• Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.

  2006cites this paper
• PPARγ-agonister – antidiabetika med gunstig effekt på kardiovaskulær risiko?

  2005cites this paper
• The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.

  2005cites this paper
• PPARa agonists: killing two birds with one stone?

  2004cites this paper
• PPARgamma agonists: killing two birds with one stone?

  2004cites this paper
• Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

  2004cites this paper
• Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action

  2004cites this paper